Loading stock data…
NVS
$147.97+2.47 (+1.70%)
Market OpenUpdated 1:15 PM EDT
Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Novartis AG in the Healthcare sector is trading at $147.97. The stock is currently 13% below its 52-week high of $170.46, remaining 9.8% above its 200-day moving average. Technical signals show neutral RSI of 47 and bearish MACD signal, explaining why NVS maintains its current momentum and trend strength. The Whystock Score of 75/100 reflects a high-conviction bullish alignment.
Ecosystem Influences
Neutral momentum (RSI 47) — price action in range
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$147.97
Potential Upside
16%
Whystock Fair Value$171.58
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus10 analysts
Hold
Mean target$153.87+4.0%
Range$123.00 – $180.00
Fundamentals
Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart f...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$284.70B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
20.63
Beta
Defensive asset. Lower volatility than the S&P 500.
0.52
Div Yield
Strong income play. Yield provides a meaningful total return floor.
322.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
29.60%
Volume
Today's trading volume
683,040
Recent News
European Bond Market Has Record Day as Rates Outlook Worsens
(Bloomberg) -- Companies flooded Europe’s bond market at a record pace, rushing to lock in funding as central banks warn the Iran conflict could reignite inflation and force interest rates higher.Most Read from BloombergUS Has Opened a Passage Through Hormuz, Central Command SaysUS Says Offensive Phase of Iran War Over as Ship Hit in StraitAnthropic Unveils AI Agents to Field Financial Services TasksTrump Pauses Plan to Guide Ships While Seeking Iran DealIran Evaluating US Proposal to End War as
This Small Biotech — Taking On AbbVie, Novartis And Sanofi — Just Catapulted Into A Breakout
Biotech stock Avalo Therapeutics skyrocketed to a two-year high Wednesday on positive results for its skin disease treatment.
Celcuity strengthens case for ASCO-spotlighted breast cancer drug
The new data could support a broader approval submission for a therapy that is already under review and set to be showcased at the year’s biggest meeting for cancer research.
Alnylam Q1 Earnings Beat Estimates, Amvuttra Sales Drive Y/Y Growth
ALNY beats Q1 earnings and revenue estimates as Amvuttra sales surge 187%, driving 96% revenue growth and offsetting declines in collaborator revenue and Onpattro sales.
Here's What Analysts Are Forecasting For Novartis AG (VTX:NOVN) After Its First-Quarter Results
As you might know, Novartis AG ( VTX:NOVN ) recently reported its quarterly numbers. Revenues of US$14b were in line...